FOXO4-DRI: preparation and storage
Intended for research use only. Not a medicinal product.
Contents (6 sections)
FOXO4-DRI: establish identity before dissolution
FOXO4-DRI is a synthetic retro-inverso peptide developed to investigate the interaction between FOXO4 and p53 in senescent cells. It is neither full-length FOXO4 protein nor a conventional L-peptide corresponding to a FOXO4 fragment. A retro-inverso construct changes sequence direction and amino-acid chirality; a single-letter sequence without D-configuration annotations does not establish identity. The original study used a defined construct, rather than an interchangeable material labelled FOXO4.
Match the full sequence, stereochemistry, terminal groups and molecular mass to the CoA. Resistance to some proteases does not establish month-long aqueous stability. In cell experiments compare senescent cells with matched nonsenescent controls, keeping seeding density, exposure time and vehicle consistent. A lower metabolic-assay signal alone does not demonstrate selective senolysis: independent cell-death measurements and checks for assay interference are needed.
Compare the stock with an authenticated reference using a method that detects the expected peptide. Routine MS confirms mass but cannot alone distinguish all stereoisomers. If the supplier does not confirm D-configuration and the reversed sequence, a peak at the expected mass does not settle identity. Retain a shared reference aliquot for comparisons across cell-assay days. A change in the proportion of senescent cells can change the response even when stock quality is unchanged.
What Baar and colleagues established
In Cell in 2017, the authors linked senescent-cell survival to the FOXO4-p53 interaction. Their engineered peptide disrupted that interaction, with p53 nuclear exclusion and apoptosis observed. Separate mouse experiments concerned doxorubicin injury, accelerated ageing and natural ageing. These are different evidence levels: cellular mechanism, tissue response and animal condition cannot be replaced by one viability assay.
Testing the proposed mechanism requires a p53-localisation or protein-interaction readout alongside an independent apoptosis measurement. If only total cell number is measured, the conclusion is limited to a change in cell abundance. An untreated culture alone cannot identify vehicle effects or senescence selectivity. Mouse findings are not an activity certificate for commercial powder.
Preparing a stock for cell comparisons
Choose aqueous buffer or cosolvent from documentation for the exact construct. Solubility of native FOXO4 or another cell-penetrating peptide does not establish FOXO4-DRI solubility. Test a small sample after transfer into final medium. Record the delay before use, tube material and any precipitate. Serially adding solvents to the whole stock to correct a poor cell response changes both the reagent and the control.
Illustrative arithmetic: 2 mg in a final 1 mL gives 2 mg/mL. Preparing 1 mL at 0.020 mg/mL requires 10 µL stock and medium to 1 mL. This is a mass calculation, not an exposure recommendation. Conversion to µM requires the verified mass of the exact retro-inverso construct including terminal groups. Match final DMSO content between groups independently of peptide concentration if the stock contains DMSO.
Assessing storage without assuming stability
D-amino acids can alter protease susceptibility but do not remove every loss mechanism. Dilute stocks may suffer adsorption, while matrix proteins change availability. Compare a stored aliquot with a fresh reference using chromatography and the same functional assay. An unchanged main-peak mass does not establish an unchanged impurity profile or cell activity.
Can the dry vial be frozen? Yes if its specification says so; short refrigerated handling likewise depends on that specification. Can leftover culture-well material be returned to stock? No: composition has changed and contamination is possible. Does clarity establish suitability? No. FOXO4-DRI construct identity, peptide integrity and selective cellular effects are separate questions, none settled by appearance alone.
When a result does not establish senolysis
A fall in senescence markers has several possible explanations. Cells may have died, changed marker expression or lost metabolic signal without being eliminated. The denominator matters: marker-positive fractions among remaining cells and absolute marker-positive cell numbers answer different questions. Retain baseline images, total nuclear counts and an independent injury measurement. This is not a new guarantee of FOXO4-DRI activity; it is a way to test whether the claimed effect is being measured.
For selectivity experiments compare concentration series in related senescent and nonsenescent cells. Different tissue origins may create apparent selectivity unrelated to senescence. Kirkland and Tchkonia discuss control difficulties: serum starvation and confluence themselves alter cell physiology. Record how senescence was induced and verified. “FOXO4-DRI was tested” without describing the model is insufficient for comparison between runs or laboratories.
For transfer to another laboratory provide the construct’s stereochemical notation, stock composition, dilution procedure, medium-contact time and selectivity criteria alongside LOT and concentration. Resolve missing stereochemical documentation before comparing results. Keeping dry reserve material separate from verified working aliquots allows investigation of storage effects without simultaneously changing batch and construct.
End of article
FOXO4-DRI
for laboratory research
Packs and current prices on the product page.